Allspring Global Investments Holdings LLC Increases Position in Repligen Co. (NASDAQ:RGEN)

Allspring Global Investments Holdings LLC lifted its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 79.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 457,065 shares of the biotechnology company's stock after buying an additional 203,011 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.82% of Repligen worth $65,395,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Ballentine Partners LLC boosted its stake in Repligen by 4.0% during the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock worth $270,000 after buying an additional 72 shares during the period. MML Investors Services LLC boosted its position in shares of Repligen by 2.7% during the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company's stock worth $503,000 after purchasing an additional 89 shares during the period. GAMMA Investing LLC increased its holdings in Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock valued at $98,000 after purchasing an additional 90 shares during the last quarter. Louisiana State Employees Retirement System raised its position in Repligen by 0.7% in the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock valued at $2,087,000 after purchasing an additional 100 shares during the period. Finally, UMB Bank n.a. lifted its stake in Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 110 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 price objective for the company. Wolfe Research initiated coverage on shares of Repligen in a research note on Thursday, November 14th. They set a "peer perform" rating on the stock. StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a research note on Friday, January 3rd. HC Wainwright cut their target price on shares of Repligen from $240.00 to $180.00 and set a "buy" rating on the stock in a research note on Thursday, January 23rd. Finally, Canaccord Genuity Group assumed coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price target for the company. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $182.91.

Repligen Stock Up 0.5 %

Repligen stock traded up $0.75 during midday trading on Monday, reaching $146.92. The company's stock had a trading volume of 402,981 shares, compared to its average volume of 563,368. The company has a market cap of $8.23 billion, a P/E ratio of -397.07, a P/E/G ratio of 4.54 and a beta of 0.99. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The business has a 50-day simple moving average of $155.26 and a 200-day simple moving average of $148.82. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.